samedan logo

 
 
spacer
home > ict > winter 2009 > strategic planning
PUBLICATIONS
International Clinical Trials

Strategic Planning

The pharmaceutical industry is experiencing tough times, facing both economic and regulatory pressures, with increasing demands for improved safety data and comparative efficacy studies, as well as late-stage pipeline failures and non-approvals by US and EU regulatory agencies. However, pharma has a wide variety of R&D strategies at its disposal to develop drug candidates faster and more efficiently. These can be implemented in isolation, but work more effectively in combination so as to optimise the linical trial process and increase the chance of clinical, and ultimately commercial, success. However, without efficient management and communication, the speed to market of a novel drug is likely to suffer.

CURRENT PROBLEMS WITH PHARMA R&D

In the increasingly competitive and cost-conscious pharmaceutical environment, it is important that pharma companies develop their pipeline products as quickly and cheaply as possible, while ensuring that they receive marketing approval as well as authorisation from the relevant reimbursement agencies. Failure to do so can have a significant economic impact and lead to company restructuring in order to balance the financial loss of drugs failing to reach the market (1).

During 2008, the number of drugs in Phase I clinical development was on the rise, but at the same time clinical trial success rates and the approval rate for new molecular entities (NMEs) were comparably low. In 2007, the FDA approved only 18 new drugs, the lowest number in 24 years (2). The number approved in 2008 was little better at 24 new approvals (3).


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Alistair Sinclair is a Senior Analyst in the Strategic Intelligence team at Datamonitor. After joining in 2003, he worked for three years in the Central Nervous System Healthcare team, producing a number of market analysis reports, focusing particularly on psychiatry drug markets. Alistair moved to the Strategic Intelligence team in 2006, and has since produced reports on a wide variety of strategic issues including lifecycle management, corporate strategies, pricing and reimbursement, sales and marketing, R&D and the emerging markets. Alistair holds a BSc from the University of Edinburgh in Medical Microbiology, and an MSc from UCL and KCMC University, Tanzania. He has also worked at the Health Protection Agency, and has published a number of papers from his research. Email: asinclair@datamonitor.com

 

spacer
Alistair Sinclair
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Signant Health Partners with Propeller Health to Gather Accurate Data on Asthma and COPD Medication Use

Philadelphia, PA – January 07, 2020: Signant Health announced today a partnership to connect TrialMax®, the industry-leading electronic Clinical Outcome Assessment (eCOA) platform, to Propeller Health’s digital health platform for asthma and COPD (chronic obstructive pulmonary disease).
More info >>

White Papers

Convergence in the Pharmaceutical Market

PCI Pharma Services

Convergence is currently playing a large part in the growth of the pharmaceutical market. The need for convergence is due to many factors including the declining economy and high competition within the sector. There are many convergences within this sector to date; these include the convergence of food based products with medical and health products and the convergence of prescription drugs to over the counter (OTC) products. Although convergence is helping the pharmaceutical industry expand and develop, it also poses some challenges; these include the regulatory outlook and counterfeiting.
More info >>

 
Industry Events

Evolution Summit

2-4 March 2020, The Meritage Resort & Spa, Napa, CA, USA

The 21st Evolution Summit is an invitation-only, premium Summit bringing leading clinical trial executives and innovative suppliers & solution providers together. The Summits content is aligned with key clinical trial challenges and interests, relevant market developments, and practical and progressive ideas and strategies adopted by successful pioneers.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement